Module 4 New PACOP BIOPHARMACEUTICS AND PHARMACOKINETICS QUESTIONS AND ANSWERS

Module 4 New PACOP BIOPHARMACEUTICS AND PHARMACOKINETICS QUESTIONS AND ANSWERS 1. It is the ability of a drug to exist in two or more crystalline form: A. Chirality B. Polymorphism C. Stereoisomerism D. A and C E. None of these 2. Arrange the following dosage forms from highest to lowest dissolution rate: I. Solution II. Capsule III. Suspension IV. Tablet A. I, II, III, IV B. I, III, II, IV C. IV, III, II, I D. IV, II, III, I E. None of these 3. All of the following statements are true regarding particle size of a drug, EXCEPT: A. Reducing the particle size can decrease the surface are of the molecule exposed to the solvent B. Reduction of particle size can be achieved by micronisation using jet mill, spray drying and air attrition methods C. The dissolution of some drugs available in the market has been improved by reducing the particle size D. Reducing the particle size of a drug may increase drug absorption E. None of these 4. Which of the following may increase drug dissolution rate? I. Too much binder II. Insoluble diluents III. High amount of lubricants A. I only B. I and II C. II and III D. I, II and III E. None of these 5. Which of the following is not true regarding the purpose of tablet coating? A. Improves palatability B. Improve aesthetic value of tablet C. Improve stability D. Improve in-vivo degradation E. None of these 6. A surface active agent that facilitates the absorption of lipophilic drug or water insoluble drugs. A. Bile B. Albumin C. Rennin D. Gastric acid E. None of these 7. Phase 2 metabolism that protects the body against chemically reactive metabolites A. Sulfate conjugation B. Glutathione conjugation C. Methylation D. Acetylation E. Glycine conjugation 8. All of the following listed below are procecesses of drug excretion, EXCEPT A. Glomerular filtration B. Active secretion C. Tubular secretion D. Tubular reabsorption E. None of these 9. It is the functional unit of the kidney A. Glomerulus B. Loop of henle C. Nephron D. Collecting tubule E. None of these 10. Creatinine clearance of a patient with kidney failure A.60-89 mL B. 30-59 mL C.15-29 mL D. <15 mL E. None of these 11. Which of the following drugs listed below will increase its clearance at alkaline urine? I. Amphetamine II. Imipramine III. Barbiturates IV. Salicylic acid A. I and II B. II and III C. III and IV D. All of these E. None of these 12. Which of the following correctly describes ion trapping? A. Changing the pH of urine used to facilitate the elimination of drug that proved to be toxic to a patient or has been taken in overdosed amount B. Administration of acidic drug to neutralize an alkaline poison in the stomach C. Alkalanizing the urine to facilitate excretion of weakly basic drugs D. A and C E. None of these 13. Discipline that applies pharmacokinetic concepts and principles in humans in order to design individualized dosage, regimens that optimize the therapeutic response of a medication while minimizing the chance of an adverse drug reaction. A. Clinical toxicology B. Clinical pharmacy C. Clinical pharmacokinetics D. Pharmacotherapeutics E. None of these 14. Chemical coversion of the drug molecule, usually by an enzymatically mediated reaction, into another chemical entity referred to as a metabolite. A. Absorption B. Distribution C. Metabolism D. Excretion E. None of these 15. Volume of serum or blood completely cleared of the drug per unit time. A. Volume of distribution B. Clearance C. Elimination D. Plasma concentration E. None of these